Denali Therapeutics ( (DNLI) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Denali Therapeutics’ stock has seen unusual fluctuations, closing at $19.59, despite holding a Strong Buy rating and a consensus price target of $40.83. The recent negative sentiment from insider trading, with key figures like COFO Alexander O. Schuth selling shares, has raised concerns. Analysts have adjusted their targets, with BTIG lowering its target due to broader market conditions and Bank of America Securities reducing theirs but noting the current weakness as a buying opportunity. The future may be influenced by positive developments, such as the FDA’s breakthrough therapy designation for Denali’s drug, tividenofusp.
More about Denali Therapeutics
YTD Price Performance: 3.17%
Average Trading Volume: 902,651
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $2.7B
For further insights into DNLI stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.